Modular Medical Inc.
MODD evidence brief
What we can confirm
- BioSniper Score:
- 5.9 / 10
- Market Cap:
- $17.9M
- Cash Runway:
- 2.0 mo
What it means
What to watch
Prepared research question
What matters most for MODD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MODD
Modular Medical Inc. (MODD) is a commercial-stage medical device company preparing for the full commercial launch of its Pivot tubeless insulin patch pump for Type 1 and Type 2 diabetes, with FDA clearance for software enhancements and initial patients actively using the device.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Modular Medical Inc..
Modular Medical Inc. (MODD) is a commercial-stage medical device company preparing for the full commercial launch of its Pivot tubeless insulin patch pump for Type 1 and Type 2 diabetes, with FDA clearance for software enhancements and initial patients actively using the device.
- Modular Medical is a commercial-stage medical device company focused on the Pivot tubeless insulin patch pump for Type 1 and Type 2 diabetes [pipeline].
- The Pivot system has received FDA 510(k) clearance and recent FDA clearance for software enhancements [pipeline][news · published 2026-09-03].
- First patients have completed onboarding and are actively using the Pivot pump in real-world settings as of July 2026 [news · published 2026-07-01].
- As of 2026-06-30, the company reported cash & equivalents of $3.9M, net income of -$6.5M, and shareholders' equity of $10.8M [sec].
- The competitive landscape includes Insulet (Omnipod), Tandem, and Medtronic [pipeline].
What works
- The Pivot pump has achieved FDA clearance and is now in real-world use with initial patients, indicating regulatory and commercial progress [news · published 2026-07-01][news · published 2026-09-03].
- The company is actively engaging with investors and the public through conferences and webinars, suggesting a structured go-to-market strategy [news · published 2026-09-08][news · published 2026-09-02].
- The Pivot system is designed as a simple, wearable, three-day insulin delivery platform, which may offer a differentiated user experience in the patch pump market [news · published 2026-09-02].
What to weigh
- The company reported a net loss of -$6.5M for the period ending 2026-06-30, indicating ongoing operating losses [sec].
- Cash & equivalents of $3.9M as of 2026-06-30 may limit the runway for full commercial launch without additional financing [sec].
- The diabetes device market is highly competitive with established players such as Insulet, Tandem, and Medtronic [pipeline].
- The company is still in the pre-full-launch phase, with commercial revenue not yet established at scale [news · published 2026-09-08].
From the filings
Quoted directly from source documents.
FDA clearance for software enhancements
“the U. Food & Drug Administration (FDA) has cleared a set of software enhancements to its Pivot insulin delivery system”
News · September 3, 2026
First patients actively using Pivot
“the first patients have completed onboarding and training and are now actively using the Pivot tubeless insulin patch pump in real-world settings”
News · July 1, 2026
Pivot is a tubeless insulin delivery system
“Pivot™ tubeless patch pump”
News · September 8, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash & equivalents of $3.9M as of 2026-06-30 may be insufficient to fund full commercial launch without additional capital [sec].
- Operating losses continue — Net loss of -$6.5M for the period ending 2026-06-30 indicates the company is not yet profitable [sec].
- Intense competitive landscape — Competitors include Insulet, Tandem, and Medtronic, all established players in the insulin delivery market [pipeline].
- Pre-revenue commercial stage — The company is still preparing for full commercial launch and has not yet reported significant product revenue [news · published 2026-09-08].
What to watch
- Full commercial launch progress and revenue generation from the Pivot pump [news · published 2026-07-01].
- Cash position and any new financing or partnership announcements following the net loss of -$6.5M as of 2026-06-30 [sec].
- Adoption rate and user feedback from the first active patients using Pivot in real-world settings [news · published 2026-07-01].
- Investor presentations and webinars, such as the iAccess Alpha conference on September 15-16, 2026, for strategic updates [news · published 2026-09-08].
Sources: Competitor trials · News · Pipeline · Generated October 2, 2026 · How we verify sources →
Run Modular Medical Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Modular Medical Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
2.0 months
D/E 0.14 · 0% dilution
Lead: Approved
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Short Interest
as of May 12, 2026- % of float
- 1.9%
- Days to cover
- 1.3
- Shares short
- 102,667
- Daily short volume (May 1, 2026)
- 81.9%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MODD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Modular Medical Inc.?
Modular Medical Inc. (MODD) is a commercial-stage medical device company preparing for the full commercial launch of its Pivot tubeless insulin patch pump for Type 1 and Type 2 diabetes, with FDA clearance for software enhancements and initial patients actively using the device.
What is Modular Medical Inc.'s lead drug candidate?
Modular Medical Inc.'s most advanced tracked candidate is pivot (Approved) for Type 1 and Type 2 diabetes.
Who is the CEO of Modular Medical Inc.?
Mr. James E. Besser is the chief executive officer of Modular Medical Inc. (MODD).
Where is Modular Medical Inc. headquartered?
Modular Medical Inc. (MODD) is headquartered in San Diego, CA, United States.
What therapeutic areas does Modular Medical Inc. focus on?
Modular Medical Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.